Physician profile
Anwar Din
NPI 1225039688
$946.71
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $161 · 2021: $31.44 · 2022: $33.78 · 2023: $193 · 2024: $213 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $197.40 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $116.34 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $89.89 | 2024-2025 | |
| Exact Sciences Corporation | $86.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.50 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $78.54 | 2019-2021 | |
| Boston Scientific Corporation | $74.63 | 2023-2024 | Watchman Access System |
| Amarin Pharma, INC. | $61.25 | 2019-2020 | |
| Baxter Healthcare | $49.86 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lilly USA, LLC | $29.89 | 2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $22.88 | 2020 | |
| Abbvie INC. | $22.37 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.84 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.